Lv1
20 积分 2023-10-09 加入
CD36-mediated endocytosis of proteolysis-targeting chimeras
5天前
已完结
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions
6天前
已完结
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression
7天前
已完结
Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants
15天前
已完结
PROTAC targeted protein degraders: the past is prologue
17天前
已完结
Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges
17天前
已完结
PROTAC targeted protein degraders: the past is prologue
19天前
已完结
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
20天前
已完结
Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor
20天前
已完结
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
22天前
已完结
皖公网安备34019202002308
